Organovo Holdings, Inc. Second Quarter Earnings Conference Call (Live)
11/08/18 at 5:00 p.m. ET
- We are a biotechnology company pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that emulate human biology and disease.
- We are developing in vivo liver tissues to treat a range of rare, life-threatening diseases, for which there are few current treatment options other than organ transplantation.
- We are capitalizing on our foundational ability to isolate highly specialized human cells to build robust, functional human tissues by creating a range of novel preclinical in vitro disease modeling platforms.
- We are striving to change the face of medicine by enabling translational drug discovery and through clinical development of novel approaches to treating disease.
|2018 Annual Report||Investor Presentation|
|Recent Investor News|
|Latest TweetsTweets by @OrganovoIR|
|Print Page | Email Page | RSS Feeds | Investor Contacts | Financial Tear Sheet|